- Home
- KPLT vs IMMX Comparison
KPLT vs IMMX Comparison
Compare KPLT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- IMMX
- Stock Information
- Founded
- KPLT 2012
- IMMX 2014
- Country
- KPLT United States
- IMMX United States
- Employees
- KPLT N/A
- IMMX N/A
- Industry
- KPLT Diversified Commercial Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- KPLT Consumer Discretionary
- IMMX Health Care
- Exchange
- KPLT Nasdaq
- IMMX Nasdaq
- Market Cap
- KPLT 33.2M
- IMMX 61.1M
- IPO Year
- KPLT N/A
- IMMX 2021
- Fundamental
- Price
- KPLT $5.92
- IMMX $2.17
- Analyst Decision
- KPLT Hold
- IMMX Strong Buy
- Analyst Count
- KPLT 2
- IMMX 1
- Target Price
- KPLT $12.00
- IMMX $7.00
- AVG Volume (30 Days)
- KPLT 24.0K
- IMMX 269.5K
- Earning Date
- KPLT 11-06-2024
- IMMX 11-12-2024
- Dividend Yield
- KPLT N/A
- IMMX N/A
- EPS Growth
- KPLT N/A
- IMMX N/A
- EPS
- KPLT N/A
- IMMX N/A
- Revenue
- KPLT $241,789,000.00
- IMMX N/A
- Revenue This Year
- KPLT $12.92
- IMMX N/A
- Revenue Next Year
- KPLT $6.30
- IMMX $200.00
- P/E Ratio
- KPLT N/A
- IMMX N/A
- Revenue Growth
- KPLT 14.99
- IMMX N/A
- 52 Week Low
- KPLT $5.79
- IMMX $1.26
- 52 Week High
- KPLT $23.54
- IMMX $7.50
- Technical
- Relative Strength Index (RSI)
- KPLT 36.71
- IMMX 53.37
- Support Level
- KPLT $6.09
- IMMX $1.88
- Resistance Level
- KPLT $6.91
- IMMX $2.44
- Average True Range (ATR)
- KPLT 0.48
- IMMX 0.32
- MACD
- KPLT -0.01
- IMMX -0.02
- Stochastic Oscillator
- KPLT 1.23
- IMMX 34.94
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.